The global biopharmaceutical CMO and CRO market was valued at USD 54.12 billion in 2030 and is anticipated to grow at a CAGR of 5.6% from 2024 to 2030 according to a new study by Grand View Research, Inc. Post-pandemic the market is being driven by the growing interest of conventional drug developers in the biological therapeutics. At present, outsourcing has become a cost-saving strategy for small- to medium-sized biomanufacturers, as it helps in eliminating the need for establishing costly specialized facilities or hiring and training personnel. The post-pandemic recovery has started owing to positive pipeline developments across modalities.

For instance, Lonza and Moderna announced a ten-year collaboration for the commercial manufacturing of the COVID-19 vaccine. Such developments compensated for minor delays in clinical trials that occurred during the first half of 2020. The contract manufacturing organization segment is projected to unlock lucrative growth opportunities over the foreseeable future. The decline in R&D productivity and increased development costs have resulted in high pressure on biopharmaceutical manufacturers pertaining to short-term earnings and profit margins. This, in turn, has created lucrative opportunities for the CMOs & CROs to accelerate their business operations.

The robustness of venture capital investments is one of the important supportive factors that has created opportunities for the growth of CMOs. Venture capital funds are considered more reliable than public equity. An increase in the availability of venture funds for life sciences is expected to bolster the growth of CMOs. However, these CMOs & CROs are expected to face competition from in-house departments of pharmaceutical & biotechnology companies. Several big pharma companies like Novartis announced to maintain and expand their biomanufacturing processes in-house over the coming years.

Gather more insights about the market drivers, restrains and growth of the Global Biopharmaceutical CMO And CRO Market

Biopharmaceutical CMO And CRO Market Report Highlights

1. Non-mammalian cell line-based bioproduction system is expected to be the fastest-growing segment over the forecast period

2. Innovative strategies are being implemented to identify and explore the potential of various microbe

3. This can be attributed to increasing investments in research programs for the development of novel therapeutics

4. The market in North America is recognized as a leader in biopharmaceutical innovations, thereby resulting in a large share of 33.9%

5. Moreover, the presence of several service providers and a higher concentration & number of biopharmaceutical firms in the region supports the market growth

6. The key players are involved in establishing mutually beneficial alliances with other emerging CMOs to scale up their production capabilities

Browse through Grand View Research's Medical Devices Industry Research Reports.

1. Tracheostomy Products Market: The global tracheostomy products market size was estimated at USD 216.9 million in 2024 and is expected to grow at a CAGR of 4.3% from 2025 to 2030.

2. Oral Syringes Market: The global oral syringes market size was valued at USD 742.5 million in 2024 and is expected to grow a CAGR of 6.1% from 2025 to 2030.

Biopharmaceutical CMO And CRO Market Segmentation

Grand View Research has segmented the global biopharmaceutical CMO & CRO Market report on the basis of source, service, product, and region:

Biopharmaceutical CMO And CRO Source Outlook (Revenue, USD Billion, 2018 - 2030)

1. Mammalian

2. Non-mammalian

Biopharmaceutical CMO And CRO Service Type Outlook (Revenue, USD Billion, 2018 - 2030)

1. Contract Manufacturing

2. Contract Research

Biopharmaceutical CMO And CRO Product Outlook (Revenue, USD Billion, 2018 - 2030)

1. Biologics

2. Biosimilars

Biopharmaceutical CMO And CRO Regional Outlook (Revenue, USD Billion, 2018 - 2030)

1. North America

2. Europe

3. Asia Pacific

4. Latin America

5. Middle East & Africa

Order a free sample PDF of the Biopharmaceutical CMO And CRO Market Intelligence Study, published by Grand View Research.